Back to search

Peptide record

TPDB41539

Seq ID No. 16 from patent ID US202000079827A1 Anticancer standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41539
Seq ID No. 16 from patent ID US202000079827A1
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 24-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
LKKWWKKVKGLLGGLLGKVKSVIK
Physicochemical Analysis
C132H228N34O26
ARNDCEQHMFPTY
K
2707.47
11.36
8
0
11
+8
1.49
0.029
133.75
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
11000
406.28
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
1
I
5
L
8
K
0
M
0
F
0
P
1
S
0
T
2
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 5 K: 8 M: 0 F: 0 P: 0 S: 1 T: 0 W: 2 Y: 0 V: 3
Chemical Descriptors
24
C132H228N34O26
2707.47
11.36
+8
1.49
0.029
Free
L
Linear
Free
Antimicrobial and Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

Cell viability
Cell viability > 50% at 20 µM
Anticancer
>50 % at 20 µM

Target

Lung Cancer
HOP-062
Lung

Assay & Model

Tetrazolium-based assay
2-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200079827A1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Cell viability
Cell viability > 50% at 20 µM
Anticancer
>50 % at 20 µM

Target

Lung Cancer
NCI-H460
Lung

Assay & Model

Tetrazolium-based assay
2-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200079827A1
Evidence 3 Activity

Activity

Cell viability
Cell viability > 50% at 20 µM
Anticancer
>50 % at 20 µM

Target

Lung Cancer
Calu-1
Lung

Assay & Model

Tetrazolium-based assay
2-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200079827A1